Nephrogenic Diabetes Insipidus

A genetic or acquired polyuric disorder characterized by persistent hypotonic urine and HYPOKALEMIA. This condition is due to renal tubular insensitivity to VASOPRESSIN and failure to reduce urine volume. It may be the result of mutations of genes encoding VASOPRESSIN RECEPTORS or aquaporin-2 (AQUAPORINS); KIDNEY DISEASES; adverse drug effects; or complications from PREGNANCY.

Also Known As:

Networked: 664 relevant articles (12 outcomes, 36 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Bipolar Disorder (Mania)
2.	Depressive Disorder (Melancholia)
3.	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus)
4.	Cystic Fibrosis (Mucoviscidosis)
5.	Wilms Tumor (Wilm's Tumor)

Experts

1.	Deen, Peter M T: 22 articles (04/2014 - 02/2002)
2.	Bichet, Daniel G: 17 articles (06/2012 - 04/2002)
3.	Nielsen, Søren: 14 articles (10/2014 - 03/2003)
4.	Sasaki, Sei: 14 articles (06/2013 - 02/2002)
5.	Kwon, Tae-Hwan: 10 articles (10/2011 - 12/2003)
6.	Verkman, A S: 8 articles (01/2012 - 04/2000)
7.	Frøkiaer, Jørgen: 8 articles (01/2009 - 12/2003)
8.	Deen, P M: 8 articles (12/2001 - 08/2000)
9.	Fenton, Robert A: 7 articles (01/2015 - 03/2008)
10.	Knepper, Mark A: 7 articles (10/2014 - 12/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Nephrogenic Diabetes Insipidus:

1.	LithiumIBA 05/01/1972 - "Lithium-induced nephrogenic diabetes insipidus: in vivo and in vitro studies." 12/01/2015 - "Lithium-induced nephrogenic diabetes insipidus is usually self-limiting or not clinically dangerous. " 06/01/2015 - "However, chronic use of lithium is often limited by the development of nephrogenic diabetes insipidus (NDI), a debilitating condition. " 06/01/2015 - "Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus." 05/15/2015 - "Mechanisms of prolonged lithium therapy-induced nephrogenic diabetes insipidus."
2.	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 01/01/2003 - "To clarify whether combination treatment with desmopressin (DDAVP) and thiazide was clinically effective in a patient with congenital nephrogenic diabetes insipidus (CNDI), we evaluated the treatment in a 7-year-old boy with CNDI who had demonstrated a partial response to DDAVP. " 01/01/2014 - "Her water deprivation test and desmopressin test results were consistent with nephrogenic diabetes insipidus. " 11/01/2010 - "Differential diagnosis of hereditary nephrogenic diabetes insipidus with desmopressin infusion test." 04/01/2009 - "Administration of 1-deamino-8-D-arginine vasopressin (dDAVP) neither decreased urine volume nor increased urine osmolality indicating congenital nephrogenic diabetes insipidus. " 01/01/2003 - "Successful treatment of partial nephrogenic diabetes insipidus with thiazide and desmopressin."
3.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 02/01/1986 - "Thus, prostaglandin synthetase inhibitors are not uniformly effective in treatment of nephrogenic diabetes insipidus. " 01/01/1981 - "Prostaglandin synthetase inhibitors in the treatment of nephrogenic diabetes insipidus." 01/01/1985 - "It is concluded that the hydrochlorothiazide-amiloride regimen is superior to hydrochlorothiazide alone and can be a satisfactory alternative to the hydrochlorothiazide-prostaglandin synthetase inhibitor combination in the treatment of congenital nephrogenic diabetes insipidus." 02/01/1986 - "The antidiuretic effect of two prostaglandin synthetase inhibitors, ibuprofen (25 mg/kg/day) and indomethacin (2 mg/kg/day), was studied in patients aged 8 to 18 years with hereditary nephrogenic diabetes insipidus. "
4.	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 04/01/2007 - "Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones." 10/01/1998 - "Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype." 09/15/1997 - "Recent studies with transfected COS-7 cells have shown that functionally inactive mutant V2 vasopressin receptors (occurring in patients with nephrogenic diabetes insipidus) can be functionally rescued by coexpression of a carboxy-terminal V2 receptor fragment (V2-tail) spanning the region where various mutations occur [Schöneberg, T., J. " 08/01/1995 - "Expression studies of two vasopressin V2 receptor gene mutations, R202C and 804insG, in nephrogenic diabetes insipidus." 10/01/1993 - "These studies demonstrated that point mutation of V2 receptor gene causes the nephrogenic diabetes insipidus. "
5.	Aquaporin 2IBA 07/01/2010 - "In the present study, we measured whether MI could increase expression of two human aquaporin 2 (AQP2) mutants which were recently identified as causing nephrogenic diabetes insipidus (NDI). " 03/01/2004 - "The aim of this study was to describe the urological complications associated with nephrogenic diabetes insipidus (NDI) due to a mutation in aquaporin-2 (AQP2), a collecting-duct protein activated by ADH signalling. " 10/01/2000 - "Importance of aquaporin-2 expression levels in genotype -phenotype studies in nephrogenic diabetes insipidus." 01/01/2015 - "Partial nephrogenic diabetes insipidus caused by a novel AQP2 variation impairing trafficking of the aquaporin-2 water channel." 01/01/2015 - "We analyzed the impact of the aquaporin 2 mutation V71M, which causes nephrogenic diabetes insipidus in humans, on aquaporin structure and activity, using the bacterial aquaglyceroporin GlpF as a model. "
6.	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 02/01/2013 - "She was diagnosed as nephrogenic diabetes insipidus due to hypercalcemia caused by hypervitaminosis D, and was treated with hydrochlorothiazide 2 mg/kg twice daily, and hydration." 12/01/2005 - "He had been diagnosed clinically with nephrogenic diabetes insipidus and treated by amiloride and hydrochlorothiazide combination without a satisfactory outcome at another center since 1 year of age. " 01/01/2004 - "Treatment of congenital nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride in an adult patient." 10/01/2003 - "Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor." 06/01/1999 - "Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride."
7.	Amiloride (Midamor)FDA LinkGeneric 12/01/1986 - "They conclude that amiloride can be useful in treating lithium-induced nephrogenic diabetes insipidus and merits future randomized clinical trials." 07/01/2009 - "Lithium therapy frequently induces nephrogenic diabetes insipidus; amiloride appears to prevent its occurrence in some clinical cases. " 09/01/2008 - "Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride." 04/01/2008 - "Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus." 12/01/2005 - "He had been diagnosed clinically with nephrogenic diabetes insipidus and treated by amiloride and hydrochlorothiazide combination without a satisfactory outcome at another center since 1 year of age. "
8.	Indomethacin (Indometacin)FDA LinkGeneric 01/01/2015 - "Two children with nephrogenic diabetes insipidus (NDI) were treated with oral indomethacin (0.75-1.2 mg/kg/day) three times a day for a mean duration of 3 yrs. " 01/01/2015 - "Response to low dose indomethacin in two children with nephrogenic diabetes insipidus." 07/01/1990 - "Six months later nephrogenic diabetes insipidus was diagnosed and indomethacin was again effectively used. " 03/01/1986 - "Indomethacin for nephrogenic diabetes insipidus in a four-week-old infant." 02/10/1980 - "[Indomethacin therapy of children with nephrogenic diabetes insipidus]."
9.	Lithium Carbonate (Eskalith)FDA LinkGeneric 07/01/2000 - "Nephrogenic diabetes insipidus persisting 57 months after cessation of lithium carbonate therapy: report of a case and review of the literature." 12/01/1990 - "Individuals receiving lithium carbonate commonly have nephrogenic diabetes insipidus. " 07/21/1979 - "Persistent nephrogenic diabetes insipidus associated with long-term lithium carbonate treatment." 04/01/1977 - "Persistent nephrogenic diabetes insipidus after lithium carbonate." 08/01/2007 - "We present a case of nephrogenic diabetes insipidus that occurred after on-pump coronary artery bypass grafting in a patient taking long-term lithium carbonate. "
10.	DiureticsIBA 05/15/2015 - "Hence, this may effectively lead to the demonstration of a novel treatment for nephrogenic diabetes insipidus, which is, at present, limited to the use of diuretics which block lithium reuptake into the body." 11/17/2002 - "Nephrogenic diabetes insipidus can be influenced by non-steroidal antiinflammatory agents or diuretics. " 01/01/2015 - "Using lithium concentrations <0.8 mmol/L; monitoring lithium concentrations and renal function every 3-6 months; being vigilant about concurrent medication use (e.g., diuretics, anti-inflammatories); as well as preventing/treating acute kidney injury, nephrogenic diabetes insipidus, diabetes mellitus, hypertension, smoking, and coronary artery disease can all help prevent CKD and further renal decline in older lithium users."

Therapies and Procedures

1.	Oral Administration 01/01/2006 - "Following oral administration of a thiazide diuretic, known to exert an antidiuretic action in nephrogenic diabetes insipidus, urine output was dramatically reduced. "
2.	Drug Therapy (Chemotherapy) 05/01/2008 - "Recently created transgenic mouse models of nephrogenic diabetes insipidus produced by AQP2 gene mutation offer exciting possibilities to test new drug therapies. " 02/01/1987 - "Transient nephrogenic diabetes insipidus following high-dose cyclophosphamide chemotherapy and autologous bone marrow transplantation." 01/01/1995 - "Nephrogenic diabetes insipidus following high dose epirubicin chemotherapy for metastatic soft tissue sarcoma."
3.	Intraperitoneal Injections 11/01/2000 - "Intraperitoneal injection of the V2 agonist, deamino-Cys(1), D-Arg(8) vasopressin, induced an increase in urine osmolarity in Clcnk1+/- and Clcnk1+/+ mice from approximately 1,000 to approximately 3,000 mosm/kg H(2)O, whereas the increase in Clcnk1-/- mice was only from approximately 600 to approximately 840 mosm/kg H(2)O, indicating nephrogenic diabetes insipidus in Clcnk1-/- mice. " 01/01/1999 - "Intraperitoneal injection of the V2 agonist 1-deamino-8-D-arginine vasopressin (dDAVP) induced a threefold increase in urine osmolarity in Clcnk1+/- and Clcnk1+/+ mice, whereas only a minimal increase was seen in Clcnk1-/- mice, indicating nephrogenic diabetes insipidus. "
4.	Perioperative Period 11/01/1994 - "Nephrogenic diabetes insipidus (NDI) presents a rarely encountered but challenging fluid management problem in the perioperative period. "
5.	Parathyroidectomy 12/01/1988 - "A 25-year-old woman with persistent nephrogenic diabetes insipidus (NDI) following parathyroidectomy for primary hyperparathyroidism is described. " 12/01/1988 - "A case with persistent nephrogenic diabetes insipidus following parathyroidectomy for hyperparathyroidism."